Key result
Primary prevention statins show uncertain net benefit in adults without established cardiovascular disease.
Answers are grounded in this paper and cite their sources.
In the US, more than 126 million adults have been diagnosed with cardiovascular disease (CVD). Accordingly, considerable resources and effort have been invested in determining not only how to effectively treat symptomatic coronary artery disease or ischemic stroke, but also on prevention of clinical CVD. Although elevated low-density lipoprotein (LDL) is associated with higher rates of CVD, 2 there is uncertainty regarding the net benefit to risk ratio of using statins to reduce LDL among persons without CVD (primary prevention). This contrasts with the established role of LDL reduction for persons with established CVD (secondary prevention).
No takes yet. Share an insight, caveat, or question.
Habib et al. (2022) conducted a review in Cardiovascular disease (primary prevention). Statins was evaluated. Using statins for primary cardiovascular disease prevention has an uncertain net benefit-to-risk ratio among persons without established cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: